Men with localized prostate cancer who received androgen deprivation therapy, a hormone treatment, were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente ...
Aug 24, 2017
0
11
Researchers from Boston University School of Medicine (BUSM) have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Jul 21, 2020
0
163
Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy. The ideal duration of treatment may be roughly two years if receiving external beam radiation and one year ...
Feb 28, 2022
0
53
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient ...
Mar 9, 2017
0
1
Scientists have discovered two separate genetic 'signatures' for prostate cancer that appear to be able to predict the severity of the disease, leading to hopes that in future, accuracy of prognosis and treatment of the disease ...
Oct 8, 2012
0
0
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer. That conclusion comes from a large randomized clinical trial ...
May 2, 2022
0
14
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Feb 10, 2014
0
0
(HealthDay)—Cholesterol-lowering statin drugs may slow down prostate cancer in men who are also taking medication to reduce their levels of male hormones, according to new research.
Mar 10, 2015
0
30
(HealthDay)—Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age, according to research published in the June issue of The Journal of Urology.
May 28, 2015
0
40
